Biobeat vs Sickbay (2026)
Two very different answers to the same gap, which is that ward patients are barely monitored between checks. Biobeat changes what data exists, putting wearable continuous monitors on patients and generating vital signs that were never collected, with a genuinely strong progressive clearance record for cuffless measurement and the widest setting coverage in this category. Sickbay changes what can be done with the data that already exists, serving high resolution physiologic capture as a vendor neutral layer that any algorithm can run on. A hospital may need both, and the question is which gap binds: no data, or data nobody can use. On Biobeat, the question to press is skin tone, because optical measurement performs differently across pigmentation and no subgroup analysis is published for a device driving automated alerts.
- It changes what data exists rather than modelling data that already does, with wearable continuous monitoring bringing vital signs to patients who are otherwise checked intermittently.
- The regulatory record is progressively built and genuinely strong across a series of clearances for cuffless measurement.
- Setting coverage is the widest in this category by design, spanning general wards, step down and home settings on one platform.
- It is the vendor neutral physiologic data layer that risk models run on, rather than a model or a device, so the institution is not locked to one algorithm.
- High resolution physiologic capture is the harder engineering problem underneath every deterioration model in the unit.
- Buying the layer separately means algorithms can be replaced without replacing the plumbing, which is the durable architectural position.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Biobeat and Sickbay are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Biobeat | Sickbay |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Inpatient Deterioration & Risk Monitoring |
| Founded | 2016 | Not recorded |
| Headquarters | Petah Tikva, Israel | Houston, Texas |
| Website | bio-beat.com | sickbay.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Biobeat its top capability grade on FDA and Regulatory Status. Set against Sickbay, Biobeat grades higher on FDA and Regulatory Status. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Sickbay on any axis it scores. Set against Biobeat, Sickbay grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Biobeat or Sickbay?
On the axes where the AI Health Index separates them, Biobeat grades higher on FDA and Regulatory Status, and Sickbay grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Sickbay leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Biobeat and Sickbay differ most?
The widest separation the AI Health Index records between Biobeat and Sickbay is on FDA and Regulatory Status, where Biobeat grades A and Sickbay grades B. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Biobeat and Sickbay grade the same?
The AI Health Index grades Biobeat and Sickbay the same on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Biobeat and Sickbay not disclosed?
At the last review, at least one of Biobeat and Sickbay published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Inpatient Deterioration & Risk Monitoring page.
The pigmentation problem is at its sharpest in this pair and only one side carries it: optical vital sign measurement is known to perform differently across skin tones, and Biobeat publishes no subgroup performance analysis for a device whose measurements drive automated early warning alerts. Ask for it explicitly. Neither vendor publishes pricing or a unit of pricing such as per monitored bed. Biobeat publishes no named record system integration, no attestation and no retention position, and its early warning score has no published threshold or alert burden figure.